tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Jun 24;8(8)
fab335.
doi: 10.1093/ofid/ofab335. eCollection 2021 Aug.
Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report
Pankaj Luitel[SUP] 1 [/SUP], Dana Vais[SUP] 2 [/SUP], Adi Gidron[SUP] 3 [/SUP]
Affiliations
Abstract
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and imdevimab) resulted in the clearance of the infection. Targeted antiviral antibodies may be an important weapon in the management of immunocompromised patients infected with severe acute respiratory syndrome coronavirus 2 who fail to mount an immune response.
Keywords: COVID-19; REGN-COV2; hypogammaglobulinemia; rituximab.
. 2021 Jun 24;8(8)
fab335.doi: 10.1093/ofid/ofab335. eCollection 2021 Aug.
Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report
Pankaj Luitel[SUP] 1 [/SUP], Dana Vais[SUP] 2 [/SUP], Adi Gidron[SUP] 3 [/SUP]
Affiliations
- PMID: 34405092
- PMCID: PMC8344477
- DOI: 10.1093/ofid/ofab335
Abstract
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and imdevimab) resulted in the clearance of the infection. Targeted antiviral antibodies may be an important weapon in the management of immunocompromised patients infected with severe acute respiratory syndrome coronavirus 2 who fail to mount an immune response.
Keywords: COVID-19; REGN-COV2; hypogammaglobulinemia; rituximab.